Onkos Surgical Reaches 1,000 Cases With 3D-Printed Pelvic Implants

A Patient-Specific Platform Hits a Milestone

Onkos Surgical has completed its 1,000th pelvic reconstruction using the My3D patient-specific implant platform. The milestone, announced August 27, reflects steady surgeon adoption of 3D-printed implants for complex orthopedic cases involving bone loss and tumors.

My3D combines advanced imaging, collaborative case planning, 3D anatomic modeling, and implant design into a single workflow. Surgeons plan each reconstruction in virtual reality before a personalized implant is printed and sterilized for the operating room. The approach removes much of the guesswork from pelvic surgery, where anatomy rarely matches textbook diagrams.

Patrick Treacy, Onkos founder and CEO, said the platform's strength lies in its ability to match implants to individual patient anatomy rather than forcing surgeons to adapt standard parts. Rick Swanson, director of patient solutions, noted that clinical insights from each case strengthen the design process for future surgeries.

The company received FDA 510(k) clearance for My3D in 2022. Since then, the platform has been used for tumor resections, trauma reconstruction, and revision cases where previous surgeries left limited bone stock. Each implant is built to order, which means lead times are longer than off-the-shelf hardware, but the fit is better and revision rates tend to be lower.

Onkos is continuing to invest in workflow optimization and implant design tools. The 1,000-case milestone gives the company a large data set to refine its models, and it signals that personalized pelvic implants are moving from experimental procedures to standard of care for complex orthopedic reconstructions.